Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants

Figures

• 

  Figure 1. Main bleeding endpoints in dual antithrombotic therapy vs. triple antithrombotic therapy. Random-effects risk ratios for main bleeding endpoints. DAT, dual antithrombotic therapy; ISTH, International Society on Thrombosis and Haemostasis; M–H, Mantel–Haenszel; TAT, triple antithrombotic therapy. With permission Gargiulo et al.9

• 

  Figure 2. Main bleeding endpoints in non-vitamin K antagonist oral anticoagulant-based dual antithrombotic therapy vs. vitamin K antagonist-based triple antithrombotic therapy. Random-effects risk ratios for main bleeding endpoints. DAT, dual antithrombotic therapy; ISTH, International Society on Thrombosis and Haemostasis; M–H, Mantel–Haenszel; TAT, triple antithrombotic therapy; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist. With Gargiulo et al.9

• 

  Figure 3. Ischaemic endpoints in dual antithrombotic therapy vs. triple antithrombotic therapy. Random-effects risk ratios for stroke, myocardial infarction and stent thrombosis. With permission Gargiulo et al.9

• 

  Figure 4. Antithrombotic therapy in atrial fibrillation patients after successful percutaneous coronary intervention. NOAC, non-vitamin K antagonist; full AF dose, dose of non-vitamin K antagonist oral anticoagulant approved by Phase III trials to prevent stroke in atrial fibrillation patients (AF); PCI, percutaneous coronary intervention; ACS, acute coronary syndrome; CCS, chronic coronary syndrome.